NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
NovoCure Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$14.89+0.82 (+5.83%)
Close on Oct 19, 2026
- Market cap
- $1.73B
- P/E (TTM)
- –
- Dividend yield
- –
NovoCure Ltd revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $385.63M | $391.80M | $349.74M | $406.89M | $353.11M | $340.78M | $232.81M | $168.41M | $134.69M | $72.77M | 58.8% | -1.6% |
| International markets - Total | $250.28M | $196.03M | $136.37M | $109.61M | $159.16M | – | – | – | – | – | 38.2% | +27.7% |
| Germany | $79.41M | $65.26M | $60.21M | $46.12M | $93.94M | $93.26M | $86.56M | $67.85M | $40.22M | $9.80M | 12.1% | +21.7% |
| France | $76.19M | $55.73M | $11.74M | $0 | – | – | – | – | – | – | 11.6% | +36.7% |
| Other international markets | $56.90M | $42.47M | $32.76M | $30.71M | $30.58M | – | – | – | – | – | 8.7% | +34.0% |
| Japan | $37.79M | $32.57M | $31.67M | $32.78M | $34.64M | $29.08M | $17.91M | $6.35M | $303.00K | $89.00K | 5.8% | +16.0% |
| China | $19.44M | $17.39M | $23.22M | $21.33M | $22.77M | $12.59M | $5.26M | $802.00K | $0 | – | 3.0% | +11.8% |
| EMEA | – | – | – | – | – | $18.65M | $8.78M | $4.65M | $1.82M | $10.03M | – | – |
| Other EMEA | – | – | – | – | $30.58M | $18.65M | $8.78M | – | – | – | – | – |
| Other EMEA | – | – | – | $30.71M | $30.58M | $18.65M | $8.78M | – | – | – | – | – |
| Others | – | – | – | $30.71M | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of NovoCure's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.